{"filing":{"accession_number":"0001437749-26-023200","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"crvo20260709_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926023200/crvo20260709_8k.htm"},"events":[{"id":16834,"run_id":15061,"accession_number":"0001437749-26-023200","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CervoMed announced completion of enrollment in a Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), with interim biomarker data accepted for presentation at CTAD and full clinical data expected in Q1 2027. This represents a material clinical development milestone for the company's pipeline.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15050,"accession_number":"0001437749-26-023200","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced completion of enrollment in a Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), with interim biomarker data expected in Q4 2026 and clinical data in Q1 2027. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the specific event types (earnings, M\u0026A, executive changes, impairment, etc.). The disclosure is clearly operational/strategic in nature—a significant trial milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:38:12.347940+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15051,"accession_number":"0001437749-26-023200","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced completion of enrollment in a Phase 2a clinical trial of neflamapimod for nfvPPA and interim biomarker data acceptance for presentation at CTAD. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the specific event types (earnings, executive changes, M\u0026A, impairment, etc.). The disclosure centers on trial progress and upcoming data presentation, which is a significant operational/strategic milestone affecting investor assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:38:12.347940+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15050,"accession_number":"0001437749-26-023200","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced completion of enrollment in a Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), with interim biomarker data expected in Q4 2026 and clinical data in Q1 2027. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the specific event types (earnings, M\u0026A, executive changes, impairment, etc.). The disclosure is clearly operational/strategic in nature—a significant trial milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:38:12.347940+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-07-09"},{"id":15051,"accession_number":"0001437749-26-023200","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced completion of enrollment in a Phase 2a clinical trial of neflamapimod for nfvPPA and interim biomarker data acceptance for presentation at CTAD. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the specific event types (earnings, executive changes, M\u0026A, impairment, etc.). The disclosure centers on trial progress and upcoming data presentation, which is a significant operational/strategic milestone affecting investor assessment of the company's pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:38:12.347940+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-07-09"}]}